Suchergebnisse
Filter
13 Ergebnisse
Sortierung:
Holocaust: the events and their impact on real people
In 7 Kapiteln, angefangen mit einem historischen Überblick zur Entstehung des Judentums bis zu den Nachwirkungen der Verfolgung, befasst sich die Autorin mit allen Bereichen des Holocausts. Das Besondere dieses Buches ist jedoch nicht die sorgsame Zusammenstellung der Fakten und ihre Illustrierung durch vorzügliches Bildmaterial, sondern die Einbindung von Zeitzeugen. Eine beiliegende DVD ermöglicht es, ihre Berichte zu sehen und zu hören und damit ihr Erleben intensiver, als es das geschriebene Wort oder ein Bild vermag, nachzuempfinden. Ein Zugang zu dem "Menschheitsverbrechen" Holocaust, der in dieser Weise zukünftig nicht mehr möglich sein wird. Unter der Überschrift "Stimmen" sind in jedem der 7 Kapitel ebenfalls Erfahrungsberichte eingeblendet, etwa über das Leben im Schtetl oder im Durchgangslager, wobei Fotos der Befragten die Anonymität des Leids durchbrechen. Dem Buch liegen die Aufzeichnungen des Instituts der Shoah-Stiftung für visuelle Geschichte und Bildung zugrunde. Zum Thema vgl. zuletzt "Massel" (Hanser, BA 4/07). Beeindruckend! Breit empfohlen, auch für die Schule.
Uranium Natives: Mining for the Cold War
Abstract: During the Cold War the quest for plutonium to produce more bombs and beat the Soviets was the mission for the Department of Energy. There was constant fear of an atomic bomb being dropped on the U.S. The search for uranium was on. People who owned mines, however, were more concerned with production than they were with safety. Unfortunately, because most of the uranium was on Indian lands, one of the biggest casualties of the race were the native communities who especially didn't understand the nature of what they were working with. Due to their traditional relationship with the earth they honestly didn't think anything from the earth would hurt them. They didn't know about radiation. Not even scientists fully understood the substance but they continued anyway, to make more weapons. Safety was a lesser concern compared to the production of weapons that we were sure the Soviets were building. What are the long term effects to the people? What is being done to clean up the mines? In my paper I plan to address these questions and more. PART OF SESSION 5A: ENVIRONMENTAL JUSTICE Comment: Jason Knirck, Central Washington UniversityChair: Elizabeth M. Swedo, Western Oregon University. Kole A. Dawson, Boise State University, graduate student"The Amungme and the Environment: Environmental Justice History and Consumerism" Margaret M. Reuter, Eastern Washington University, undergraduate student"Hanford: Leaking Tanks and Human Health" Angela M. Wood, Eastern Washington University, undergraduate student"Uranium Natives: Mining for the Cold War"
BASE
Accountability of the International Monetary Fund
In: Voices in development management
Holocaust: was damals geschah ; [Überlebende berichten auf DVD]
In 7 Kapiteln, angefangen mit einem historischen Überblick zur Entstehung des Judentums bis zu den Nachwirkungen der Verfolgung, befasst sich die Autorin mit allen Bereichen des Holocausts. Das Besondere dieses Buches ist jedoch nicht die sorgsame Zusammenstellung der Fakten und ihre Illustrierung durch vorzügliches Bildmaterial, sondern die Einbindung von Zeitzeugen. Eine beiliegende DVD ermöglicht es, ihre Berichte zu sehen und zu hören und damit ihr Erleben intensiver, als es das geschriebene Wort oder ein Bild vermag, nachzuempfinden. Ein Zugang zu dem "Menschheitsverbrechen" Holocaust, der in dieser Weise zukünftig nicht mehr möglich sein wird. Unter der Überschrift "Stimmen" sind in jedem der 7 Kapitel ebenfalls Erfahrungsberichte eingeblendet, etwa über das Leben im Schtetl oder im Durchgangslager, wobei Fotos der Befragten die Anonymität des Leids durchbrechen. Dem Buch liegen die Aufzeichnungen des Instituts der Shoah-Stiftung für visuelle Geschichte und Bildung zugrunde. Zum Thema vgl. zuletzt "Massel" (Hanser, BA 4/07). Beeindruckend! Breit empfohlen, auch für die Schule.
Motivational Interviewing and Chronic Care Management Using the Transtheoretical Model of Change
In: Health & social work: a journal of the National Association of Social Workers, Band 48, Heft 4, S. 271-276
ISSN: 1545-6854
Abstract
The number of Americans living with chronic health conditions has steadily increased. Chronic diseases are the leading causes of death and disability in the United States and cost the healthcare system an estimated $4.1 trillion dollars a year. The role of social workers in assisting patients in the management of their chronic diseases is vital. The behavioral health changes often required of chronic care management (CCM) patients require support and intervention by professionals to help the patient improve self-management of their chronic health conditions. Motivational interviewing (MI) is an evidence-based practice that helps people change by paying attention to the language patients use as they discuss their change goals and behaviors. Applying the principles and strategies of MI within the stages of change model (transtheoretical model of change) can help social workers better understand and assist patients receiving CCM. This article outlines specific strategies the social worker can use to address motivation at different stages of change.
Alcohol intake in relation to fatal and non-fatal incident coronary heart disease and stroke in the EPIC-CVD study
ABSTRACT Objective To investigate the association between alcohol consumption (at baseline and over lifetime) and non-fatal and fatal coronary heart disease (CHD) and stroke. Design Multicentre case-cohort study. Setting A study of cardiovascular disease (CVD) aetiology (EPIC-CVD) within the European Prospective Investigation into Cancer and nutrition cohort from 8 European countries. Participants A case-cohort study of 32 549 participants without baseline CVD, comprised of incident CVD cases and a subcohort for comparison. Main outcome measure Non-fatal and fatal CHD and stroke (including ischaemic and haemorrhagic). Results There were 9307 non-fatal CHD, 1699 fatal CHD, 5855 non-fatal stroke and 733 fatal stroke events. Baseline alcohol intake was inversely associated with non-fatal CHD, with a hazard ratio of 0.94 (95% confidence interval 0.92 to 0.96) per 12 g/day higher intake. There was a J-shaped association between baseline alcohol intake and risk of fatal CHD (hazard ratios=0.83 [95% confidence interval 0.70 to 0.98], 0.65 [0.53 to 0.81], and 0.82 [0.65 to 1.03] for categories 5.0-14.9 g/day, 15.0-29.9 g/day, and 30.0-59.9 g/day, respectively, compared with 0.1-4.9 g/day. In contrast, hazard ratios for non-fatal and fatal stroke risk were 1.04 (95% confidence interval 1.02 to 1.07), and 1.05 (0.98 to 1.13) per 12 g/day increase in baseline alcohol intake, respectively, including broadly similar findings for ischaemic and haemorrhagic stroke. Associations with cardiovascular outcomes were broadly similar with average lifetime alcohol consumption as for baseline alcohol intake, and across the eight countries we studied. There was no strong evidence for interactions of alcohol consumption with smoking status on the risk of CVD events. Conclusions Alcohol intake was inversely associated with non-fatal CHD risk but positively associated with risk of different stroke subtypes, highlighting the opposing associations of alcohol intake with different cardiovascular disease types and strengthening the evidence for policies to reduce alcohol consumption. ; This work was supported by the Direction Générale de la Santé (French Ministry of Health) (grant GR-IARC-2003-09-12-01). EPIC-CVD has been supported by the European Union Framework 7 (HEALTH-F2-2012-279233), the European Research Council (268834), the UK Medical Research Council (G0800270 and MR/L003120/1), the British Heart Foundation (SP/09/002 and RG/08/014 and RG13/13/30194), and the UK National Institute of Health Research. The establishment of the random subcohort was supported by the EU Sixth Framework Programme (FP6) (grant LSHM_CT_2006_037197 to the InterAct project) and the Medical Research Council Epidemiology Unit (grants MC_UU_12015/1 and MC_UU_12015/5).
BASE
Motivational Interviewing: A Qualitative Examination of Factors Impacting Adoption and Implementation in a Community-Wide Setting
In: Journal of social work practice in the addictions, Band 11, Heft 4, S. 336-351
ISSN: 1533-2578
Plant foods, dietary fibre and risk of ischaemic heart disease in the EPIC cohort
Background: Epidemiological evidence indicates that diets rich in plant foods are associated with a lower risk of ischaemic heart disease (IHD), but there is sparse information on fruit and vegetable subtypes and sources of dietary fibre. This study examined the associations of major plant foods, their subtypes and dietary fibre with risk of IHD in EPIC. Methods: We conducted a prospective analysis of 490,311 men and women in ten European countries without a history of myocardial infarction or stroke at recruitment (12.6 years of follow-up, n cases=8504). Dietary intake was assessed using validated questionnaires, calibrated with 24-hour recalls. Multivariable Cox regressions were used to estimate hazard ratios (HR) of IHD. Results: There was a lower risk of IHD with a higher intake of fruit and vegetables combined (HR per 200 g/day higher intake 0.94, 95% CI:0.90-0.99, P-trend=0.009), and total fruits (per 100g/day 0.97, 0.95-1.00, P-trend=0.021). There was no evidence for a reduced risk for fruit subtypes, except for bananas. Risk was lower with higher intakes of nuts and seeds (per 10g/day 0.90, 0.82-0.98, P-trend=0.020), total fibre (per 10g/day 0.95, 0.85-0.98, P-trend=0.015), fruit and vegetable fibre (per 4g/day 0.95, 0.91-0.99, P-trend=0.022), and fruit fibre (per 2 g/day 0.97, 0.95-1.00, P-trend=0.045). No associations were observed between vegetables, vegetables subtypes, legumes, cereals and IHD risk. Conclusions: In this large prospective study, we found some small inverse associations between plant foods and IHD risk, with fruit and vegetables combined being the most strongly inversely associated with risk. Whether these small associations are causal remains unclear. ; Analyses supported by the UK Medical Research Council (MR/M012190/1), Cancer Research UK (C8221/A19170 and 570/A16491), and the Wellcome Trust (Our Planet Our Health, Livestock Environment and People 205212/Z/16/Z). APC is supported by a Cancer Research UK Population Research Fellowship (C60192/A28516) and by the World Cancer Research Fund (WCRF UK), as part of the Word Cancer Research Fund International grant programme (2019/1953). EPIC-CVD has been supported by the European Union Framework 7 (HEALTH-F2-2012-279233), the European Research Council (268834), the UK Medical Research Council (G0800270 and MR/L003120/1), the British Heart Foundation (SP/09/002 and RG/08/014 and RG13/13/30194), and the UK National Institute of Health Research. The InterAct project was funded by the EU FP6 programme (grant number LSHM_CT_2006_037197), and provided the biomarker data in the subcohort that was used in the current study. The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l'Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF) (Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF); Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andalucía, Asturias, Basque Country, Murcia (no. 6236) and Navarra, ISCIII RETIC (RD06/0020) (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to EPIC-Oxford), UK Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford, MC_UU_12015/1 (NJW), MC_UU_12015/5 (NGF), and MC_UU_12015/520, and NIHR Biomedical Research Centre Cambridge: Nutrition, Diet, and Lifestyle Research Theme (IS-BRC-1215-20014) to the MRC Epidemiology Unit Cambridge (NJW, NGF). JD holds a British Heart Foundation Chair and an NIHR Senior Investigator Award. KEB holds a Girdlers' New Zealand Health Research Council Fellowship.
BASE
A genome-wide meta-analysis yields 46 new loci associating with biomarkers of iron homeostasis
Iron is essential for many biological functions and iron deficiency and overload have major health implications. We performed a meta-analysis of three genome-wide association studies from Iceland, the UK and Denmark of blood levels of ferritin (N=246,139), total iron binding capacity (N=135,430), iron (N=163,511) and transferrin saturation (N=131,471). We found 62 independent sequence variants associating with iron homeostasis parameters at 56 loci, including 46 novel loci. Variants at DUOX2, F5, SLC11A2 and TMPRSS6 associate with iron deficiency anemia, while variants at TF, HFE, TFR2 and TMPRSS6 associate with iron overload. A HBS1L-MYB intergenic region variant associates both with increased risk of iron overload and reduced risk of iron deficiency anemia. The DUOX2 missense variant is present in 14% of the population, associates with all iron homeostasis biomarkers, and increases the risk of iron deficiency anemia by 29%. The associations implicate proteins contributing to the main physiological processes involved in iron homeostasis: iron sensing and storage, inflammation, absorption of iron from the gut, iron recycling, erythropoiesis and bleeding/menstruation. ; Participants in the INTERVAL randomised controlled trial were recruited with the active collaboration of NHS Blood and Transplant England (www.nhsbt.nhs.uk), which has supported field work and other elements of the trial. DNA extraction and genotyping was co-funded by the National Institute for Health Research (NIHR), the NIHR BioResource (http://bioresource.nihr.ac.uk/) and the NIHR [Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust] [*]. The academic coordinating centre for INTERVAL was supported by core funding from: NIHR Blood and Transplant Research Unit in Donor Health and Genomics (NIHR BTRU-2014-10024), UK Medical Research Council (MR/L003120/1), British Heart Foundation (SP/09/002; RG/13/13/30194; RG/18/13/33946) and the NIHR [Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust] [The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care]. A complete list of the investigators and contributors to the INTERVAL trial is provided in reference 73. The academic coordinating centre would like to thank blood donor centre staff and blood donors for participating in the INTERVAL trial. Professor John Danesh is funded by the National Institute for Health Research [Senior Investigator Award]. Will Astle, Joanna Howson and Tao Jiang are funded by the National Institute for Health Research [Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust]. Angela M Wood and Elias Allara are supported by EC-Innovative Medicines Initiative (BigData@Heart). Praveen Surendran is supported by a Rutherford Fund Fellowship from the Medical Research Council grant MR/S003746/1. This work was supported by Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome. The Novo Nordisk Foundation (NNF14CC0001 and NNF17OC0027594). The Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 115881 (RHAPSODY) (Karina Banasik and Søren Brunak). The Danish Administrative Regions; The Danish Administrative Regions' Bio- and Genome Bank; The authors thank all the blood banks in Denmark for both collecting and contributing data to this study. Danish Blood Donor Research Fund. Aarhus University, Copenhagen University Hospital Research Fund. Competing interests: Henrik Ullum received an unrestricted research grant form Novartis. Cristian Erikstrup received an unrestricted research grant from Abbott. Søren Brunak reports grants from Innovation Fund Denmark, grants from Novo Nordisk Foundation during the conduct of the study; and personal fees from Intomics A/S and Proscion A/S, outside the submitted work. For the authors who are affiliated with deCODE genetics/Amgen, we declare competing financial interests as employees.
BASE
Conducting a Large Public Health Data Collection Project in Uganda: Methods, Tools, and Lessons Learned
We report on the implementation experience of carrying out data collection and other activities for a public health evaluation study on whether U.S. President's Emergency Plan for AIDS Relief (PEPFAR) investment improved utilization of health services and health system strengthening in Uganda. The retrospective study period focused on the PEPFAR scale-up, from mid-2005 through mid-2011, a period of expansion of PEPFAR programing and health services. We visited 315 health care facilities in Uganda in 2011 and 2012 to collect routine health management information system data forms, as well as to conduct interviews with health system leaders. An earlier phase of this research project collected data from all 112 health district headquarters, reported elsewhere. This article describes the lessons learned from collecting data from health care facilities, project management, useful technologies, and mistakes. We used several new technologies to facilitate data collection, including portable document scanners, smartphones, and web-based data collection, along with older but reliable technologies such as car batteries for power, folding tables to create space, and letters of introduction from appropriate authorities to create entrée. Research in limited-resource settings requires an approach that values the skills and talents of local people, institutions and government agencies, and a tolerance for the unexpected. The development of personal relationships was key to the success of the project. We observed that capacity building activities were repaid many fold, especially in data management and technology.
BASE
Risk thresholds for alcohol consumption : combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies
Background: Low-risk limits recommended for alcohol consumption vary substantially across different national guidelines. To define thresholds associated with lowest risk for all-cause mortality and cardiovascular disease, we studied individual-participant data from 599 912 current drinkers without previous cardiovascular disease. Methods: We did a combined analysis of individual-participant data from three large-scale data sources in 19 high-income countries (the Emerging Risk Factors Collaboration, EPIC-CVD, and the UK Biobank). We characterised dose–response associations and calculated hazard ratios (HRs) per 100 g per week of alcohol (12·5 units per week) across 83 prospective studies, adjusting at least for study or centre, age, sex, smoking, and diabetes. To be eligible for the analysis, participants had to have information recorded about their alcohol consumption amount and status (ie, non-drinker vs current drinker), plus age, sex, history of diabetes and smoking status, at least 1 year of follow-up after baseline, and no baseline history of cardiovascular disease. The main analyses focused on current drinkers, whose baseline alcohol consumption was categorised into eight predefined groups according to the amount in grams consumed per week. We assessed alcohol consumption in relation to all-cause mortality, total cardiovascular disease, and several cardiovascular disease subtypes. We corrected HRs for estimated long-term variability in alcohol consumption using 152 640 serial alcohol assessments obtained some years apart (median interval 5·6 years [5th–95th percentile 1·04–13·5]) from 71 011 participants from 37 studies. Findings: In the 599 912 current drinkers included in the analysis, we recorded 40 310 deaths and 39 018 incident cardiovascular disease events during 5·4 million person-years of follow-up. For all-cause mortality, we recorded a positive and curvilinear association with the level of alcohol consumption, with the minimum mortality risk around or below 100 g per week. Alcohol consumption was roughly linearly associated with a higher risk of stroke (HR per 100 g per week higher consumption 1·14, 95% CI, 1·10–1·17), coronary disease excluding myocardial infarction (1·06, 1·00–1·11), heart failure (1·09, 1·03–1·15), fatal hypertensive disease (1·24, 1·15–1·33); and fatal aortic aneurysm (1·15, 1·03–1·28). By contrast, increased alcohol consumption was log-linearly associated with a lower risk of myocardial infarction (HR 0·94, 0·91–0·97). In comparison to those who reported drinking >0–≤100 g per week, those who reported drinking >100–≤200 g per week, >200–≤350 g per week, or >350 g per week had lower life expectancy at age 40 years of approximately 6 months, 1–2 years, or 4–5 years, respectively. Interpretation: In current drinkers of alcohol in high-income countries, the threshold for lowest risk of all-cause mortality was about 100 g/week. For cardiovascular disease subtypes other than myocardial infarction, there were no clear risk thresholds below which lower alcohol consumption stopped being associated with lower disease risk. These data support limits for alcohol consumption that are lower than those recommended in most current guidelines. Funding: UK Medical Research Council, British Heart Foundation, National Institute for Health Research, European Union Framework 7, and European Research Council.
BASE
Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies
BACKGROUND: Low-risk limits recommended for alcohol consumption vary substantially across different national guidelines. To define thresholds associated with lowest risk for all-cause mortality and cardiovascular disease, we studied individual-participant data from 599 912 current drinkers without previous cardiovascular disease. METHODS: We did a combined analysis of individual-participant data from three large-scale data sources in 19 high-income countries (the Emerging Risk Factors Collaboration, EPIC-CVD, and the UK Biobank). We characterised dose-response associations and calculated hazard ratios (HRs) per 100 g per week of alcohol (12·5 units per week) across 83 prospective studies, adjusting at least for study or centre, age, sex, smoking, and diabetes. To be eligible for the analysis, participants had to have information recorded about their alcohol consumption amount and status (ie, non-drinker vs current drinker), plus age, sex, history of diabetes and smoking status, at least 1 year of follow-up after baseline, and no baseline history of cardiovascular disease. The main analyses focused on current drinkers, whose baseline alcohol consumption was categorised into eight predefined groups according to the amount in grams consumed per week. We assessed alcohol consumption in relation to all-cause mortality, total cardiovascular disease, and several cardiovascular disease subtypes. We corrected HRs for estimated long-term variability in alcohol consumption using 152 640 serial alcohol assessments obtained some years apart (median interval 5·6 years [5th-95th percentile 1·04-13·5]) from 71 011 participants from 37 studies. FINDINGS: In the 599 912 current drinkers included in the analysis, we recorded 40 310 deaths and 39 018 incident cardiovascular disease events during 5·4 million person-years of follow-up. For all-cause mortality, we recorded a positive and curvilinear association with the level of alcohol consumption, with the minimum mortality risk around or below 100 g per week. Alcohol consumption was roughly linearly associated with a higher risk of stroke (HR per 100 g per week higher consumption 1·14, 95% CI, 1·10-1·17), coronary disease excluding myocardial infarction (1·06, 1·00-1·11), heart failure (1·09, 1·03-1·15), fatal hypertensive disease (1·24, 1·15-1·33); and fatal aortic aneurysm (1·15, 1·03-1·28). By contrast, increased alcohol consumption was log-linearly associated with a lower risk of myocardial infarction (HR 0·94, 0·91-0·97). In comparison to those who reported drinking >0-≤100 g per week, those who reported drinking >100-≤200 g per week, >200-≤350 g per week, or >350 g per week had lower life expectancy at age 40 years of approximately 6 months, 1-2 years, or 4-5 years, respectively. INTERPRETATION: In current drinkers of alcohol in high-income countries, the threshold for lowest risk of all-cause mortality was about 100 g/week. For cardiovascular disease subtypes other than myocardial infarction, there were no clear risk thresholds below which lower alcohol consumption stopped being associated with lower disease risk. These data support limits for alcohol consumption that are lower than those recommended in most current guidelines. FUNDING: UK Medical Research Council, British Heart Foundation, National Institute for Health Research, European Union Framework 7, and European Research Council.
BASE